136,300 Shares in Kymera Therapeutics, Inc. $KYMR Acquired by Eagle Health Investments LP

Eagle Health Investments LP acquired a new stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR) during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 136,300 shares of the company’s stock, valued at approximately $10,606,000. Kymera Therapeutics makes up about 2.3% of Eagle Health Investments LP’s portfolio, making the stock its 14th biggest position.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in KYMR. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Kymera Therapeutics by 6.3% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,793 shares of the company’s stock valued at $849,000 after acquiring an additional 1,833 shares in the last quarter. Millennium Management LLC lifted its position in Kymera Therapeutics by 340.4% in the 1st quarter. Millennium Management LLC now owns 510,480 shares of the company’s stock valued at $13,972,000 after acquiring an additional 394,562 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Kymera Therapeutics by 121.5% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 896,404 shares of the company’s stock valued at $24,535,000 after acquiring an additional 491,737 shares in the last quarter. Invesco Ltd. lifted its position in Kymera Therapeutics by 13.8% in the 2nd quarter. Invesco Ltd. now owns 47,884 shares of the company’s stock valued at $2,090,000 after acquiring an additional 5,809 shares in the last quarter. Finally, Sei Investments Co. bought a new position in Kymera Therapeutics in the 2nd quarter valued at approximately $265,000.

Analysts Set New Price Targets

Several equities analysts recently issued reports on KYMR shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kymera Therapeutics in a research report on Tuesday, April 21st. Citigroup upped their price objective on Kymera Therapeutics from $110.00 to $120.00 and gave the company a “buy” rating in a research report on Monday, March 2nd. Morgan Stanley reaffirmed an “overweight” rating and issued a $119.00 price objective on shares of Kymera Therapeutics in a research report on Thursday, April 30th. Stephens upped their price objective on Kymera Therapeutics from $95.00 to $100.00 and gave the company an “overweight” rating in a research report on Monday, March 2nd. Finally, Jefferies Financial Group started coverage on Kymera Therapeutics in a research report on Monday, March 16th. They issued a “buy” rating and a $110.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Kymera Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $118.10.

Kymera Therapeutics Price Performance

NASDAQ KYMR opened at $80.65 on Thursday. The business’s fifty day moving average price is $83.31 and its 200-day moving average price is $78.44. The stock has a market capitalization of $6.63 billion, a price-to-earnings ratio of -22.59 and a beta of 2.06. Kymera Therapeutics, Inc. has a 1-year low of $28.06 and a 1-year high of $103.00.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings results on Thursday, April 30th. The company reported ($0.71) earnings per share for the quarter, beating the consensus estimate of ($0.89) by $0.18. The firm had revenue of $34.37 million for the quarter, compared to analysts’ expectations of $8.27 million. Kymera Therapeutics had a negative return on equity of 24.71% and a negative net margin of 611.94%.The company’s revenue was up 55.5% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.82) EPS. Equities research analysts anticipate that Kymera Therapeutics, Inc. will post -3.34 EPS for the current year.

Insider Activity

In other news, insider Noah Goodman sold 8,264 shares of the stock in a transaction on Thursday, April 9th. The stock was sold at an average price of $87.50, for a total transaction of $723,100.00. Following the transaction, the insider directly owned 53,542 shares of the company’s stock, valued at $4,684,925. This represents a 13.37% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Nello Mainolfi sold 30,000 shares of the stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $90.26, for a total value of $2,707,800.00. Following the transaction, the chief executive officer directly owned 666,195 shares in the company, valued at $60,130,760.70. The trade was a 4.31% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 383,734 shares of company stock worth $32,454,902. Insiders own 15.98% of the company’s stock.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.